Catalent Inc (NYSE:CTLT) Shares Sold by MetLife Investment Advisors LLC
MetLife Investment Advisors LLC trimmed its holdings in shares of Catalent Inc (NYSE:CTLT) by 41.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,822 shares of the company’s stock after selling 59,983 shares during the period. MetLife Investment Advisors LLC owned 0.06% of Catalent worth $3,511,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Redmile Group LLC acquired a new position in shares of Catalent in the second quarter valued at approximately $27,725,000. Champlain Investment Partners LLC boosted its holdings in Catalent by 19.2% during the first quarter. Champlain Investment Partners LLC now owns 3,627,390 shares of the company’s stock worth $148,941,000 after purchasing an additional 583,675 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in Catalent by 25.2% during the second quarter. Macquarie Group Ltd. now owns 2,349,059 shares of the company’s stock worth $98,402,000 after purchasing an additional 472,228 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Catalent by 59.8% during the first quarter. Wells Fargo & Company MN now owns 1,146,493 shares of the company’s stock worth $47,074,000 after purchasing an additional 429,061 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new position in Catalent during the second quarter worth $16,387,000. Hedge funds and other institutional investors own 91.76% of the company’s stock.
Several research analysts recently commented on the stock. UBS Group started coverage on shares of Catalent in a report on Tuesday. They set a “neutral” rating and a $48.00 target price for the company. Zacks Investment Research raised shares of Catalent from a “sell” rating to a “hold” rating in a research report on Monday, October 1st. JPMorgan Chase & Co. upped their price target on shares of Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 29th. Finally, ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $49.33.
Catalent stock traded down $0.02 during trading hours on Friday, reaching $41.47. 976,559 shares of the stock were exchanged, compared to its average volume of 947,037. The company has a market capitalization of $6.61 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 2.71 and a beta of 1.40. The company has a quick ratio of 1.79, a current ratio of 2.15 and a debt-to-equity ratio of 2.44. Catalent Inc has a twelve month low of $36.73 and a twelve month high of $47.87.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, August 28th. The company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.06. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The firm had revenue of $685.30 million for the quarter, compared to the consensus estimate of $690.69 million. During the same period in the prior year, the company posted $0.65 earnings per share. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. On average, sell-side analysts expect that Catalent Inc will post 1.72 earnings per share for the current year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: What is a conference call?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.